The mitral valve potential market has become one of the most potential markets in recent medical devices history. InValv has developed a novel procedure that form a structure implanted through one catheter access and that is strongly bounded to the mitral structures. InValv has a very strong IP portfolio position on this technology.
After FIH completed, InVavl’s valuation is anticipated to be in the $500+ mm